NEW YORK (GenomeWeb) – Molecular diagnostics developer Paradigm announced today that it has reached an agreement with UnitedHealthcare for insurance coverage of its next-generation sequencing-based cancer diagnostic test PCDx.

The diagnostic is designed to identify the genomic and proteomic alterations underlying a patient's tumor DNA, RNA, and proteins, leading to a more personalized and targeted approach to treatment.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.